Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Rhea-AI Summary

Blueprint Medicines (NASDAQ: BPMC) has announced that it will host a live conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and provide a corporate update. Interested parties can access the live conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and referring to conference ID 387547.

A webcast of the call will also be available under the 'Events and Presentations' section of the company's Investors & Media webpage. The archived webcast will be accessible on Blueprint Medicines' website approximately two hours after the conference call and will remain available for 30 days following the call.

CAMBRIDGE, Mass., Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, October 30, 2024, to report its third quarter 2024 financial results and provide a corporate update.

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 387547. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-third-quarter-2024-financial-results-on-wednesday-october-30-2024-302275822.html

SOURCE Blueprint Medicines Corporation

FAQ

When will Blueprint Medicines (BPMC) report its Q3 2024 financial results?

Blueprint Medicines (BPMC) will report its third quarter 2024 financial results on Wednesday, October 30, 2024, during a live conference call and webcast at 8:00 a.m. ET.

How can investors access Blueprint Medicines' (BPMC) Q3 2024 earnings call?

Investors can access Blueprint Medicines' Q3 2024 earnings call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and using conference ID 387547. A webcast will also be available on the company's website.

Where can I find the webcast for Blueprint Medicines' (BPMC) Q3 2024 earnings call?

The webcast for Blueprint Medicines' Q3 2024 earnings call will be available under the 'Events and Presentations' section in the Investors & Media area of the company's website at http://ir.blueprintmedicines.com/.

How long will the archived webcast of Blueprint Medicines' (BPMC) Q3 2024 earnings call be available?

The archived webcast of Blueprint Medicines' Q3 2024 earnings call will be available on the company's website for 30 days following the call.